The program is intended to accelerate US drug manufacturing scale-ups and address unmet patient needs. Two companies familiar to our regenerative readers, Cellares and Fujifilm Biotechnologies, made the list!
Following Phase 3, TREGZI, known as Orca-T, had higher graft-versus-host disease-free survival at one year in patients receiving conventional blood stem cell transplants.
The company's lead program, HS-001, required open heart surgery, while the new innovation allows for a much simpler, less invasive administration.
Verismo is ramping up its 2 Phase 1s targeting solid tumors and B-Cell non-Hodgkin lymphomas, selecting Cryoport for its cold chain.
The California agency is hoping to accelerate the cell & gene therapy industry amid uncertainty about federal funding.
The company is hoping to be the 2nd Taiwanese cell therapy approved abroad.
The Chinese company also received an IND in China a few weeks ago. Supported by good preclinical data, they'll advance clinical trials in both countries soon.
The embryonic-derived cell therapy is implanted directly into the brain, and this early trial hopes to establish safety and baseline efficacy.
PLA General Hospital has begun recruiting 2,000 adults aged 50 and older for a multicenter randomized trial to assess whether an approved umbilical cord mesenchymal stem cell therapy can safely improve aging-related...
Based on the RCT results published in The Lancet, the Chinese biotech company has received approval for the world's first CAR-T for solid tumors.
